Clinical Trials Sponsored by Enimmune Corporation

Total 7101 results

Enimmune Corporation

Enrolling by invitation

A Study to Evaluate the Efficacy, Immunogenicity and Safety of an EV71 Vaccine in Healthy Infants and Children

Enterovirus Infections

Taiwan, Vietnam
Enimmune Corporation

Completed

A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects

Enterovirus Infections

Taiwan
Enimmune Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old

Enterovirus Infections

Taiwan
Adimmune Corporation

Completed

Dose-finding Study for AdimrSC-2f Vaccine

COVID-19

Indonesia
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects

Influenza
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of AdimFlu-S, Formulation 2010-2011, in Infants Aged Between 6-12months Old

Influenza

Taiwan
Adimmune Corporation

Completed

A Pharmacovigilance Study for AdimFlu-S (A/H1N1) Influenza Vaccine in Pregnant Women

Adverse Drug Reactions
Regimmune Corporation

Completed

RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

Graft Vs Host Disease | Graft-versus-host-disease | Acute-graft-versus-host Disease | Prevention of aGVHD

United States
Adimmune Corporation

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

Pandemic Influenza

Taiwan
Adimmune Corporation

Completed

A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old

Influenza
Adimmune Corporation

Completed

Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects

Influenza

Taiwan
Adimmune Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine

COVID-19

Taiwan
Regimmune Corporation

Completed

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Graft Versus Host Disease

United States
Adimmune Corporation

Completed

Immunogenicity and Safety Evaluation of QIS in Healthy Subjects

Influenza
Adimmune Corporation

Completed

The Safety and Immune Response to Influenza Vaccination in Pregnant Women

Influenza

Taiwan
Adimmune Corporation

Completed

A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population

Influenza

Taiwan
Inimmune Corporation
Avance Clinical Pty Ltd.

Not yet recruiting

Trial of INI-4001 in Patients With Advanced Solid Tumours

Advanced Solid Tumor

Australia
Inimmune Corporation
Avance Clinical Pty Ltd.

Recruiting

Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis.

Allergic Rhinitis | Allergic Rhinitis Due to Weed Pollen

Australia
Epimmune

Completed

An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Lung Neoplasm

United States
Epimmune

Completed

An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer

Colorectal Neoplasms | Colonic Neoplasms

United States
Rockefeller University
Immune Design; IDRI Corporation

Completed

The Effects of GLA on Human Volunteers

Healthy Volunteers

United States
Zachariah Michael DeFilipp
Regimmune Corporation

Active, not recruiting

Haplo Peripheral Blood Sct In GVHD Prevention

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | AML | Non Hodgkin Lymphoma | MDS | Myeloproliferative Disorder | GVHD | Graft Vs Host Disease | ALL | CMML | Blood Stem Cell Transplant Failure | MPN | Chemosensitive Hodgkin Lymphoma

United States
Epimmune
Pharmexa A/S; Pharmexa-Epimmune

Unknown

A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART) (EP1090)

HIV Infections

United States
NImmune Biopharma

Terminated

Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

Crohn's Disease

United States
NImmune Biopharma

Completed

Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers

Normal Healthy Volunteers

Australia
NImmune Biopharma

Withdrawn

Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease

Crohn's Disease
NImmune Biopharma

Completed

Efficacy and Safety of Oral BT-11 in Ulcerative Colitis

Ulcerative Colitis

United States, Bosnia and Herzegovina, Croatia, Poland, Ukraine
NImmune Biopharma

Withdrawn

Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis

Eosinophilic Esophagitis
NImmune Biopharma

Completed

Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers

Normal Healthy Volunteers

United States
Afimmune

Recruiting

Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

Sickle Cell Disease

United States
Afimmune

Terminated

Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis

Severe Acute Decompensated Alcoholic Hepatitis

United States, Georgia
Afimmune

Completed

Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United Kingdom
MedImmune LLC
MedImmune Ltd

Completed

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Bulgaria, Poland, Russian Federation, Estonia, Hungary, Latvia, Lithuania, Romania, Ukraine, Czechia, Japan
MedImmune LLC
MedImmune Ltd

Completed

Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

Asthma

United States, Brazil, Bulgaria, Mexico, Peru, Poland, Russian Federation, Argentina, Canada, Colombia
MedImmune Ltd

Completed

A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Germany
Afimmune

Terminated

Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes (TRIAGE)

Type 2 Diabetes | Hypertriglyceridemia

Georgia, United States, Germany, Israel, Latvia, Switzerland
Afimmune

Completed

Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD

Non Alcoholic Fatty Liver Disease

Georgia, Ukraine, United Kingdom
MedImmune LLC
MedImmune Ltd

Completed

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Bulgaria, Poland, Russian Federation, South Africa, Spain, Estonia, Hungary, Ukraine, Argentina, Chile, Germany, Serbia, Czech Republic, Colombia
CoImmune

Terminated

Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

United States
GenMont Biotech Incorporation
Biomedical Development Corporation

Completed

the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis (PAR)

Probiotics | Perennial Allergic Rhinitis | Lactobacillus Paracasei GMNL-32 (eN-Lac®)

Taiwan
MedImmune LLC
AstraZeneca; MedImmune Ltd

Completed

A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects

Healthy

United States
NexImmune Inc.

Not yet recruiting

Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Oropharyngeal Cancer | Human Papilloma Virus | Head and Neck Cancer Metastatic | HPV-Related Squamous Cell Carcinoma | Oropharyngeal Cancer, Metastatic | HPV-Related Mucosal Head and Neck Squamous... and other conditions
MedImmune LLC

Active, not recruiting

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States, Italy, Spain, Taiwan, Korea, Republic of, China, Hong Kong, Japan, Singapore
MedImmune LLC

Active, not recruiting

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Advanced Solid Tumors

United States, Spain, Belgium, Italy, Korea, Republic of, Canada, Australia, Hungary, United Kingdom, France, New Zealand
MedImmune LLC

Completed

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)

Stage III Non-small Cell Lung Cancer | Unresectable

United States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
MedImmune LLC

Terminated

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Metastatic Microsatellite-stable Colorectal Cancer

United States, Spain, France, Australia, Canada

Clinical Trials Sponsored by Enimmune Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations